Advantan

Advantan is a branded family of topical dermatological medicines whose active ingredient is methylprednisolone aceponate, a corticosteroid. Products under the name are used for inflammatory skin conditions that respond to topical corticosteroid treatment; the precise approved uses and available formulations depend on local product information and authorization. Advantan is a medicine brand, not a food or general consumer-staples product, so the supplied food classification does not fit the subject. The brand’s corporate history reflects successive ownership of prescription dermatology products rather than the creation of an independent company. Advantan was part of Bayer’s prescription dermatology portfolio. In July 2018, Bayer and Danish pharmaceutical company LEO Pharma announced an agreement for LEO Pharma to acquire Bayer’s global prescription dermatology business, a portfolio that explicitly included Advantan. The US business transferred in September 2018, while the remaining global business transferred on July 1, 2019. LEO Pharma’s current German dermatology information lists Advantan among its products and provides product information for several formulations. The brand includes 0.1% methylprednisolone aceponate products in forms such as cream, ointment, fatty ointment, emulsion marketed as milk, and solution in Germany. These presentations differ in their vehicle and intended skin-use characteristics; availability varies by country. The official product materials identify the active ingredient and provide formulation-specific instructions and safety information. Advantan is a prescription medicine in some markets, and it should be used according to the locally approved product information and advice from a qualified healthcare professional. The brand’s market footprint is international, with official or regulatory references documenting availability in Germany, Austria, Australia, and Uganda. LEO Pharma’s acquisition announcement described the transaction as covering the global prescription dermatology business, with staged transfers across markets. The product’s present identity is therefore best understood as an established topical corticosteroid brand within LEO Pharma’s medical-dermatology portfolio, rather than as a standalone pharmaceutical company. Publicly available material consulted for this entry supports the ownership transition and product range, but does not establish a reliable original launch year, founder, or a distinct history of Advantan-specific advertising campaigns or scandals.

Advantan is a pharmaceutical product brand for topical medicines containing methylprednisolone aceponate. Its history is documented chiefly through the ownership and transfer of prescription dermatology products, rather than through a separately incorporated business or a well-documented independent founding story. Available references do not establish a dependable original launch year or identify an individual founder for the brand. Bayer’s prescription dermatology business included Advantan before its sale to LEO Pharma. Bayer’s announcement described Advantan as one of its established topical steroid brands and explained that the business had grown within Bayer after becoming part of the company in 2006. The wider portfolio also included prescription treatments in other dermatology areas. LEO Pharma, a Danish pharmaceutical company headquartered in Ballerup, agreed in July 2018 to acquire that global prescription dermatology unit. The stated strategic rationale was to expand LEO Pharma’s medical dermatology business and add established prescription brands and treatment areas to its portfolio. The change in ownership was implemented in stages. The US business transferred to LEO Pharma in September 2018. The remaining global prescription dermatology business transferred on July 1, 2019. Bayer’s reporting identifies Advantan among the brands in the divested portfolio, while LEO Pharma’s own history records the acquisition of Bayer’s dermatology portfolio in 2018. Current LEO Pharma materials for Germany list Advantan and provide professional and patient information for its local product presentations. The German product family includes cream, ointment, fatty ointment, milk emulsion, and solution, each containing 0.1% methylprednisolone aceponate according to LEO Pharma materials. Formulation lists are market-specific and should not be taken to mean that every presentation is authorized or sold in every country. Public records also document Advantan products in Austria, Australia, and Uganda. As with other topical corticosteroid medicines, its approved indications, dispensing status, instructions, and warnings are governed by the applicable local product information. Advantan is currently best described as an established LEO Pharma medical-dermatology brand. No reliable material reviewed for this entry substantiates a distinct Advantan corporate headquarters, separate management team, founder, original launch date, or a significant brand-specific campaign or scandal. Accordingly, those fields are left unset rather than inferred from the history of its former or current corporate owners.

• 2019

  Remaining global prescription dermatology business transfers to LEO Pharma

  [4]Bayer Half-Year Report 2020: completion of dermatology business transferrelease.ace.bayer.com

  The remaining business outside the United States, including Advantan, transferred to LEO Pharma on July 1, 2019.

• 2018

  LEO Pharma announces agreement to acquire Bayer’s prescription dermatology unit

  [3]Bayer and LEO Pharma announce acquisition of Bayer’s prescription dermatology unitbayer.com

  The announced portfolio included Advantan and other prescription dermatology brands. The transfer was scheduled in stages across markets.

• 2018

  US prescription dermatology business transfers to LEO Pharma

  [4]Bayer Half-Year Report 2020: completion of dermatology business transferrelease.ace.bayer.com

  Bayer reported that the US portion of the prescription dermatology business transferred to LEO Pharma on September 4, 2018.

• 2006

  Advantan becomes part of Bayer’s prescription dermatology business

  [3]Bayer and LEO Pharma announce acquisition of Bayer’s prescription dermatology unitbayer.com

  Bayer later described the prescription dermatology business, which included Advantan, as having grown within Bayer since becoming part of the company in 2006.

A prescription-led medical dermatology brand offering multiple topical corticosteroid formulations based on methylprednisolone aceponate. Formulation availability and approved use vary by market.

• Topical corticosteroid cream

  Advantan 0.1% cream

  A cream formulation containing methylprednisolone aceponate 0.1% (1 mg/g), listed in LEO Pharma’s German product materials. The cream is one presentation in the Advantan topical dermatology range. Its approved uses, directions, contraindications, and availability should be checked against the current product information for the relevant country.

• Topical corticosteroid ointment

  Advantan 0.1% ointment

  An ointment presentation containing methylprednisolone aceponate 0.1% (1 mg/g). It is listed alongside the brand’s other formulations in LEO Pharma’s German product information. Product details and authorized use are market-specific.

• Topical corticosteroid fatty ointment

  Advantan 0.1% fatty ointment

  A fatty ointment formulation containing methylprednisolone aceponate 0.1% (1 mg/g), included in the German Advantan product range. The presentation differs from the standard ointment in its formulation vehicle; consult local approved information for its specific use and precautions.

• Topical corticosteroid emulsion

  Advantan 0.1% milk emulsion

  A topical emulsion marketed in Germany as Advantan Milch, containing methylprednisolone aceponate 0.1% (1 mg/g). It is one of several vehicle options in the brand family. Its approved indications and availability depend on local authorization and product information.

• Topical corticosteroid solution

  Advantan 0.1% solution

  A solution presentation containing methylprednisolone aceponate 0.1% (1 mg/g), listed in LEO Pharma’s German professional product materials. It forms part of the country-specific range and should be used only in accordance with its local approved labeling.

• 2018

  Agreement to transfer Bayer’s prescription dermatology business, including Advantan, to LEO PharmaM&A

  Background

  Bayer agreed to sell its global prescription dermatology unit to LEO Pharma. The portfolio included topical steroid brands such as Advantan, alongside prescription treatments in other dermatology categories.

  Action taken

  The parties announced the agreement in July 2018 and completed the transfer in stages: the US business moved in September 2018, followed by the remaining global business on July 1, 2019.

  Aftermath

  Advantan became part of LEO Pharma’s prescription dermatology portfolio. The transaction concerned a broader business unit, and no brand-specific purchase price is asserted here.

  Source

• 2019

  Transfer of Bayer’s remaining global prescription dermatology portfolio to LEO Pharma completed[4]Bayer Half-Year Report 2020: completion of dermatology business transferrelease.ace.bayer.com

  M&A

  Bayer reported that the remaining prescription dermatology business outside the United States, including Advantan, transferred to LEO Pharma on July 1, 2019.

• 2018

  LEO Pharma agrees to acquire Bayer’s prescription dermatology business, including Advantan[3]Bayer and LEO Pharma announce acquisition of Bayer’s prescription dermatology unitbayer.com

  M&A

  Bayer and LEO Pharma announced an agreement covering Bayer’s global prescription dermatology unit. The portfolio named Advantan among its topical corticosteroid brands. The transfer took place in stages, with the US business moving in 2018 and the remaining global business in 2019.

1. 1LEO Pharma product information: Advantan and other dermatology productsde.dermaworld.eu
2. 2LEO Pharma, contact and corporate addressleo-pharma.com
3. 3Bayer and LEO Pharma announce acquisition of Bayer’s prescription dermatology unitbayer.com
4. 4Bayer Half-Year Report 2020: completion of dermatology business transferrelease.ace.bayer.com
5. 5LEO Pharma historyleo-pharma.com
6. 6Australian Commission on Safety and Quality in Health Care: Advantan medicine informationsafetyandquality.gov.au
7. 7Uganda National Drug Authority: National Drug Register of Human Medicinesnda.or.ug